Lawsuit alleges SNY delayed Lemtrada approval to obviate the need to pay full value for Genzyme-derived CVR: http://www.reuters.com/article/2015/11/10/us-sanofi-genzyme-lawsuit-idUSKCN0SZ02U20151110 Approval-time CVR milestones should be graduated rather than binary, IMO, to avert this kind of disagreement.